Compare Redwire Corporation (RDW) vs 10X Genomics Inc (TXG) Price & Performance

Redwire (RDW) trades at $8.60, down 1.78% with a bearish technical signal despite oversold RSI readings. The company shows strong revenue growth potential with a record $492 million backlog and a 1.92 book-to-bill ratio, but faces significant profitability challenges with a net income margin of -80.9% and consecutive earnings misses. Recent expansions in Indiana and Alabama highlight operational growth amid substantial cash burn from operations.

The stock presents a high-risk, high-reward opportunity with an 80% analyst buy rating and a $19.00 consensus price target implying over 120% upside. However, persistent losses, negative cash flow from operations, and potential dilution from a $500 million ATM offering pose substantial risks to near-term shareholder value.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.